International Journal of Drug Policy
Volume 21, Issue 2 , Pages 134-136, March 2010

Moving from a project to programmatic response: Scaling up harm reduction in Asia

  • Anindya Chatterjee

      Affiliations

    • HIV/AIDS Asia Regional Program, Thailand
    • Tel.: +66 818022453.
  • ,
  • Mukta Sharma

      Affiliations

    • Technical Support Unit, HIV/AIDS Asia Regional Program, Thailand
    • Corresponding Author InformationCorresponding author. Tel.: +66 81 2552453.

Received 12 October 2009; received in revised form 16 December 2009; accepted 17 December 2009. published online 15 January 2010.

Abstract 

The response to the HIV epidemics among people who inject drugs in Asia began to emerge in the early to mid 1990s, with the rather hesitant implementation of small-scale needle syringe programmes and community care initiatives aiming to support those who were already living with the virus. Since then Asia has seen a significant scaling up of harm reduction, despite very limited resources and difficult policy and legislative environments. One of the major reasons this has happened, is the utilisation of programme based approaches and the firm entrenchment of harm reduction thinking within national HIV/AIDS programmes and strategic plans—in most cases aided by multilateral and bilateral donors. Several models of scale up have been noted in Asia. The transition away from project based approaches, while on the whole positive, can also have a negative impact if the involvement of civil society and a client focussed approach is not protected. Also there are implications for which models of capacity building can be systematised for ongoing scale up. Most crucially, the tensions between drug policy, human rights and public health policies need to be resolved if harm reduction services are to be made available to the millions in Asia who are still unable to access these services.

Keywords: HIV, Asia, Harm reduction, Needle syringe programmes, Coverage, National response

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0955-3959(09)00165-0

doi:10.1016/j.drugpo.2009.12.004

International Journal of Drug Policy
Volume 21, Issue 2 , Pages 134-136, March 2010